Wed, Sep 17, 2014, 5:54 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Regenerx Biopharmaceuticals Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • snogreen snogreen Jul 28, 2011 10:26 AM Flag

    RegeneRx Set to Begin Enrolling Phase 2 Dry Eye Trial

    YES! Thank you wondergirl!. Here is important stuff:

    <<ROCKVILLE, Md.--[Major Traders]--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) has announced that it is set to begin a Phase 2 clinical trial in 72 patients with dry eye syndrome. The Company anticipates enrollment of the first patients on August 13th, and expects preliminary data from the study to be available in October 2011. The trial is a double-masked, placebo-controlled trial testing the safety and efficacy of RGN-259, the Company’s proprietary preservative-free eye drops, against a placebo. Patients will receive RGN-259 or placebo twice daily for 30 days. Signs and symptoms of dry eye, such as the degree of ocular surface damage, ocular itching, burning and inflammation, among others, will be measured periodically during the treatment period. The trial will be conducted by ORA Inc., an ophthalmic contract research organization that specializes in dry eye research and clinical trials. Additional details regarding the Phase 2 trial may be seen online at: “We have received Institutional Review Board approval for the trial, completed manufacturing of RGN-259 and placebo, and are currently preparing for enrollment of the first patients”

    “We have received Institutional Review Board approval for the trial, completed manufacturing of RGN-259 and placebo, and are currently preparing for enrollment of the first patients,” stated J.J. Finkelstein, RegeneRx’s president and chief executive officer. “This is a very important clinical trial for RegeneRx that is based on a body of human and preclinical data that suggest RGN-259 could have beneficial effects in treating dry eye. Everyone at RegeneRx, as well as those associated with the project, are encouraged about the prospects for RGN-259 to improve the signs and symptoms associated with dry eye syndrome, a condition with limited treatment options.”

 
RGRX
0.1322-0.0008(-0.60%)Sep 17 1:40 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.